Hostname: page-component-848d4c4894-cjp7w Total loading time: 0 Render date: 2024-06-19T15:18:21.535Z Has data issue: false hasContentIssue false
  • English
  • Français

Forty-three-year-old woman with mediastinal PEComa treated with chemoradiation therapy

Published online by Cambridge University Press:  22 January 2014

Tommy Sheu ,
Joella Wilson  and
Larry Steven Carpenter
Tommy Sheu*
Affiliation:
Department of Radiology, Baylor College of Medicine, Houston, TX, USA
Joella Wilson
Affiliation:
Department of Radiology, Baylor College of Medicine, Houston, TX, USA
Larry Steven Carpenter
Affiliation:
Department of Radiology, Baylor College of Medicine, Houston, TX, USA
*
Correspondence to: Tommy Sheu, Department of Radiology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. Tel: 713 798 6362; Fax: 713 798 8359. E-mail: tsheu@bcm.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

The rarity of PEComa tumours has precluded any clinical trials, but surgery remains the most commonly reported treatment modality with just a few reports on treatment plans involving chemoradiation. We describe a patient with a mediastinal PEComa who presented with symptoms concerning for superior vena cava syndrome. She was deemed inoperable and was thus treated exclusively with chemoradiation therapy. The use of chemoradiation in the treatment of PEComa tumours is reviewed.

Keywords

chemoradiationmediastinal tumourPEComasuperior vena cava syndrome
Type
Case Study
Information
Journal of Radiotherapy in Practice , Volume 14 , Issue 1 , March 2015 , pp. 80 - 83
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Hornick, J L, Fletcher, C D M. PEComa: what do we know so far? Histopathology 2006; 48: 75–82.CrossRefGoogle ScholarPubMed
2.Aydin, H, Magi-Galluzzi, C M, Lane, B Ret al. Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol 2009; 33 (2): 289–297.Google Scholar
3.Fang, C L, Lin, Y H, Chen, W Y. Microscopic endometrial perivascular epithelioid cell nodules: a case report with the earliest presentation of a uterine perivascular epithelioid cell tumor. Diagn Pathol 2012; 7: 117.Google Scholar
4.Welling, R D, Lungren, M P, Coleman, R E. Extrarenal retroperitoneal angiomyolipoma mimicking metastatic melanoma. Clin Nucl Med 2012; 37: 705–706.CrossRefGoogle ScholarPubMed
5.Prieto, V G, Shea, C R. Immunohistochemistry of melanocytic proliferations. Arch Pathol Lab Med 2011; 135: 853–859.CrossRefGoogle ScholarPubMed
6.Suase, W T, Cooper, J S, Rush, Set al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991; 20 (3): 429–432.CrossRefGoogle Scholar
7.Quirbt, I, Verma, S, Petrella, Tet al. Temozolomide for the treatment of metastatic melanoma. Curr Oncol 2007; 14 (1): 27–33.Google Scholar
8.Bonetti, F, Martignoni, G, Colato, Cet al. Abdominopelvic sarcoma of perivascular epithelioid cells. Report of four cases in young women, one with tuberous sclerosis. Mod Pathol 2001; 14 (8): 563–568.CrossRefGoogle ScholarPubMed
9.Jeon, I, Lee S, M. Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus. J Pediatr Hematol Oncol 2005; 27: 681–684.CrossRefGoogle Scholar
10.Gennatas, C, Michalaki, V, Kairi, P V, Kondi-Paphiti, A, Voros, D. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol 2012; 10 (1): 181.Google Scholar